293 related articles for article (PubMed ID: 26359463)
1. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
Abou Ltaif S; Herbert L
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
[TBL] [Abstract][Full Text] [Related]
2. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
[TBL] [Abstract][Full Text] [Related]
3. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
Modi YS; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
[TBL] [Abstract][Full Text] [Related]
4. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
[TBL] [Abstract][Full Text] [Related]
5. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
[TBL] [Abstract][Full Text] [Related]
6. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
[TBL] [Abstract][Full Text] [Related]
7. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology.
Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P
Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990
[TBL] [Abstract][Full Text] [Related]
8. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.
Katz RS
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(3):239-42. PubMed ID: 24708167
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
[TBL] [Abstract][Full Text] [Related]
10. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
[TBL] [Abstract][Full Text] [Related]
11. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
[TBL] [Abstract][Full Text] [Related]
12. ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.
Tadayoni R; Holz FG; Zech C; Liu X; Spera C; Stalmans P
Retina; 2019 Dec; 39(12):2341-2352. PubMed ID: 30308558
[TBL] [Abstract][Full Text] [Related]
13. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.
Dugel PU; Regillo C; Eliott D
Am J Ophthalmol; 2015 Jul; 160(1):94-9.e1. PubMed ID: 25818925
[TBL] [Abstract][Full Text] [Related]
15. EXPERIENCE WITH OCRIPLASMIN IN PATIENTS WITH VITREOMACULAR TRACTION SYNDROME: A RETROSPECTIVE STUDY OF 10 PATIENTS.
Bormann C; Apitzsch BC; Habermann A; Hammer U; Hammer T
Retin Cases Brief Rep; 2020; 14(4):377-380. PubMed ID: 29621042
[TBL] [Abstract][Full Text] [Related]
16. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
[No Abstract] [Full Text] [Related]
17. Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
Jeng KW; Baumal CR; Witkin AJ; Witkin SR; Wiegand TW; Waheed NK
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):271-4. PubMed ID: 25707057
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
[TBL] [Abstract][Full Text] [Related]
19. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
Varma R; Haller JA; Kaiser PK
JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
Shaikh M; Miller JB; Papakostas TD; Husain D
Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
